badger, I agree on the cost of a new, experienced, biotech-seasoned CEO. If the company hired a new CEO this week that met the qualifications some desire, at a salary high enough to get them to come to the company, we'd likely hear endless bitching about the salary and bonuses structure for a "pre-revenue" company. I have no doubt in my mind the new CEO salary would be a major bitching point.

Hard to imagine some are calling for Gerald's replacement when the company is within 2 months of generating revenue from LymPro.

The path to this point hasn't been a perfect execution, but given how many different things GC has juggled to get here, I am more inclined to give him another year to let his efforts play out. I imagine when everything going on behind the scenes comes to fruition, sentiments toward our CEO will be quite different.

Instead of focusing on the drop from $0.19 to the current level, I remain focused on the significant gains I've made in this investment since I began purchasing almost 2 years ago. I guess that's how it will go with this investment... happy shareholders when the price spikes, and unhappy shareholders when there is a downturn.